Nanobiotix Presents Early Data on Lung Cancer Treatment
Nanobiotix has presented initial results from a randomized Phase 2 study evaluating JNJ-1900 (NBTXR3) for inoperable stage III lung cancer, showing promising response rates.
French clinical-stage biotechnology company Nanobiotix announced the presentation of initial data from its Phase 2 CONVERGE study. The study evaluates the first-in-class nanoradioenhancer JNJ-1900 (NBTXR3) for the treatment of inoperable stage III non-small cell lung cancer.
The data were presented by Johnson & Johnson at the 2026 European Lung Cancer Conference (ELCC). Preliminary findings from seven patients indicated promising signs, with an observed objective response rate (ORR) of 71.4%, compared to an estimated benchmark of 45-50%. The disease control rate (DCR) was reported at 100%.
The treatment was described as well-tolerated, with no serious treatment-related adverse events observed. JNJ-1900 (NBTXR3) consists of functionalized hafnium oxide nanoparticles administered via a single intratumoral injection and activated by radiotherapy. Its mechanism is designed to enhance tumor cell destruction and trigger an adaptive immune response.
Nanobiotix suggests that JNJ-1900 (NBTXR3)'s physical mechanism of action makes it adaptable to all solid tumors treatable with radiotherapy and suitable for various therapeutic combinations, particularly with checkpoint inhibitors. The company is continuing development through collaborations, including a licensing agreement with Janssen, a Johnson & Johnson company.